1h Free Analyst Time
The central nervous system (CNS) stimulant drugs market is forecasted to grow by USD 8.60 billion during 2024-2029, accelerating at a CAGR of 6.7% during the forecast period. The report on the central nervous system (CNS) stimulant drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by approval of new stimulants, growing research and development, and increasing clinical trials by companies.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The central nervous system (CNS) stimulant drugs market is segmented as below:
By Distribution Channel
- Hospitals
- Others
By Application
- Attention-deficit hyperactivity disorder
- Narcolepsy
- Others
By Route Of Administration
- Oral tablets and capsules
- Injectables
- Transdermal patches
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the central nervous system (CNS) stimulant drugs market covers the following areas:
- Central Nervous System (CNS) Stimulant Drugs Market sizing
- Central Nervous System (CNS) Stimulant Drugs Market forecast
- Central Nervous System (CNS) Stimulant Drugs Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Distribution Channel
9 Market Segmentation by Application
10 Market Segmentation by Route of Administration
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global central nervous system (CNS) stimulant drugs market: Astellas Pharma Inc., Azurity Pharmaceuticals Inc., Elite Pharmaceuticals Inc., Hisamitsu Pharmaceutical Co. Inc., Ironshore, Jazz Pharmaceuticals Plc, KemPharm Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, Sanofi SA, SHIONOGI Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Tris Pharma Inc., and Viatris Inc..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increased uptake of new-generation drugs."
According to the report, one of the major drivers for this market is the approval of new stimulants.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Astellas Pharma Inc.
- Azurity Pharmaceuticals Inc.
- Elite Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Ironshore
- Jazz Pharmaceuticals Plc
- KemPharm Inc.
- Merck and Co. Inc.
- Novartis AG
- Pfizer Inc.
- Purdue Pharma LP
- Sanofi SA
- SHIONOGI Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Thermo Fisher Scientific Inc.
- Tris Pharma Inc.
- Viatris Inc.
